Posts

LAS VEGAS, NV / ACCESSWIRE / October 12, 2015 / (OTCQB:VRCI) Verde Science, Inc., a Pharmaceutical Research and Development Company focused on developing a portfolio of cannabis-based prescription medicines to meet patients’ needs for a wide range of medical conditions, is pleased to announce it will be sponsoring and presenting at the twenty-third annual Huntington Study Group Conference (http://huntingtonstudygroup.org/) This year’s conference, HSG 2015: Building Our Future is being held from October 21-24, 2015 at the Grand Hyatt, Tampa Bay, FL.

Harp Sangha, CEO of Verde Science commented, “We are honored to sponsor this important conference and to do our part to improve the outcomes and lives of people who suffer this condition”.

About Verde Science, Inc. (VRCI-OTCQB)
Verde Science, Inc. (trading symbol VRCI-OTCQB) is an early stage pharmaceutical organization that has built a research team focused on developing a portfolio of cannabinoid prescription medicines to meet patient needs in a wide range of medical conditions. Verde’s scientists have identified a number of promising areas in which to begin its immediate R&D program, which will initially be based in India. The Verde Science team of inter-disciplinary researchers includes scientists in Bioprocess Engineering, Nanotechnology, Molecular Biology, Pharmaceutical Sciences and Bio-Medical Devices that is focused on a streamlined approach to the development of innovative treatment protocols aimed at capturing considerable market share.

Information
For further information please see our investor profile available on our website: www.verdescienceinc.com.

Contact
Harp Sangha, Chairman
Tel:        1-604-825-1309
Email:   hsangha@verdescienceinc.com
Facebook:  goo.gl/gxQFZz

Safe Harbor Statements
Certain information contained in this news release constitutes “forward-looking statements” as such term is used in applicable United States and Canadian laws. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “expects” or “does not expect,” “is expected,” “anticipates” or “does not anticipate,” “plans,” “estimates,” “intends” or “believes,” or that certain actions, events or results “may,” “could,” “would,” “might” or “will be taken,” “occur,” or “be achieved.” Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made, and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the SEC. Such risks and other factors include, among others, the ability to locate and acquire suitable interests in alternative medicine manufacturing operations on terms acceptable to the Company, the availability of financing on acceptable terms, accidents, labor disputes, acts of God and other risks of the alternative medicine industry including, without limitation, delays in obtaining governmental approvals or permits, title disputes or claims limitations on insurance coverage. The Company believes that the expectations reflected in the forward-looking statements included in this news release are reasonable; however, no assurance can be given that these expectations will prove to be correct, and such forward-looking statements should not be unduly relied upon. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

LAS VEGAS, Oct. 9, 2015 (Globe Newswire) – Verde Science, Inc. (VRCI), a Pharmaceutical Research and Development Company focused on developing a portfolio of cannabinoid based prescription medicines to meet patients’ needs for a wide range of medical conditions, is pleased to announce that along with some renowned research scientists it intends to study the treatment potential of a cannabis preparation (Nabiximols) in the treatment of Huntingdon’s Disease as a sponsor at 2 universities in North America. The study as currently designed will be a double-blind, placebo controlled protocol with 48 subjects.

Harp Sangha, CEO of Verde Science commented, “We will be embarking on our first research study into the potential of cannabis preparations to treat medical conditions and improve lives. Our team is excited to approach this milestone and is hopeful that it will lead to an efficacious and commercially viable pharmaceutical product and additional research studies for treating other medical conditions.”

About Verde Science, Inc. (VRCI-OTCQB)
Verde Science, Inc. (trading symbol VRCI-OTCQB) is an early stage pharmaceutical organization that has built a research team focused on developing a portfolio of cannabinoid prescription medicines to meet patient needs in a wide range of medical conditions. Verde’s scientists have identified a number of promising areas in which to begin its immediate R&D program, which will initially be based in India. The Verde Science team of inter-disciplinary researchers includes scientists in Bioprocess Engineering, Nanotechnology, Molecular Biology, Pharmaceutical Sciences and Bio-Medical Devices that is focused on a streamlined approach to the development of innovative treatment protocols aimed at capturing considerable market share.

Information
For further information please see our investor profile available on our website: www.verdescienceinc.com.

Contact
Harp Sangha, Chairman
Tel:        1-604-825-1309
Email:   hsangha@verdescienceinc.com
Facebook:  goo.gl/gxQFZz

Safe Harbor Statements
Certain information contained in this news release constitutes “forward-looking statements” as such term is used in applicable United States and Canadian laws. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “expects” or “does not expect,” “is expected,” “anticipates” or “does not anticipate,” “plans,” “estimates,” “intends” or “believes,” or that certain actions, events or results “may,” “could,” “would,” “might” or “will be taken,” “occur,” or “be achieved.” Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made, and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the SEC. Such risks and other factors include, among others, the ability to locate and acquire suitable interests in alternative medicine manufacturing operations on terms acceptable to the Company, the availability of financing on acceptable terms, accidents, labor disputes, acts of God and other risks of the alternative medicine industry including, without limitation, delays in obtaining governmental approvals or permits, title disputes or claims limitations on insurance coverage. The Company believes that the expectations reflected in the forward-looking statements included in this news release are reasonable; however, no assurance can be given that these expectations will prove to be correct, and such forward-looking statements should not be unduly relied upon. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.